AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The new Zigly center features and offers comprehensive veterinary services
This marks the fourth acquisition by Corona Remedies from multinational corporations
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
A triple-action Formula for comprehensive respiratory relief
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Subscribe To Our Newsletter & Stay Updated